The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Premaitha launches Iona test as it gets CE mark ..shares up but more to come

By Tom Winnifrith | Sunday 8 February 2015

Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

A few weeks earlier than we had expected, Premaitha Health (NIPT) has announced that it has received CE-mark approval for its Iona test and will therefore launch it commercially at once. This is good news and the shares are now 23.5p – 24.5p.

The IONA® test uses next-generation sequencing technology to estimate the risk of a fetus having Down's syndrome (Trisomy 21), Edwards' syndrome (Trisomy 18) and Patau's syndrome (Trisomy 13)  - it is more sensitive and specific than the current combined test, providing accurate and reliable screening results to pregnant women. And it means fewer invasive tests and thus fewer miscarriages.

The potential market is vast. The question is how quickly can Premaitha monitise this and my conversations suggest we could get news on that very soon which will spark a further re-rating of the share price.

House broker Panmure Gordon has upped its target from 23p to 28p and will undoubtedly up it again when the first sales are announced. We tipped this at a 15p offer, the target remains 30p to sell. There is still upside and we expect news on commercialisation very shortly to deliver this. At worst a strong hold

This article first appeared  on the Nifty Fifty website run by Tom Winnifrith, Steve Moore and Lucian Miers - sorry paying customers come first. To read Lucian's next shorting idea next weekend and to catch the next value investment share tip from Tom & Steve out shortly click HERE

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on NIPT



  1. Turned into a stonking tip for me ………. thanks a lot.

  2. 30p to sell in the near future. From your discussions Tom, where do you think the share price for Premaitha might be in a year or so for holders with a longer term outlook?

  3. Tom, I was thinking about holding on too so would be interested in what you think longer term? Thanks.

  4. Dont know about you guys ,but this looks like a buy and retire share if ever I saw one . If you got in low enough and big enough that is. I got in at the bottom but no where near big enough in hind sight .
    Have to say that Opti whatsit is shaping up very well too . Tell you what , Tom can certainly find these gems out of nowhere . They were not even on my radar screen prior to Tom pointing them out. Its always important to give praise where praise is due . He gets enough shit to fill London sewage works so he needs a pat to keep the motivation up I would imagine .

  5. Chis Standing

    Not Good news

Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.

Site by Everywhen